Abbott (ABT) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Over the past ...

Polen Capital, an investment management company, released its “Polen Focus Growth Strategy” first-quarter 2026 investor ...

Abbott Laboratories (NYSE: ABT) more or less met analyst estimates in its first quarter, the results of which were published ...

Abbott Laboratories (ABT) is back in focus after presenting new multi-biomarker data for its Cancerguard multi cancer early ...

Investors in Abbott Laboratories ABT need to pay close attention to the stock based on moves in the options market lately. That is because the Sep 18, 2026 $70 Call had some of the highest implied ...

Is ABT a good stock to buy? We came across a bullish thesis on Abbott Laboratories on Compounding Dividends’s Substack by TJ Terwilliger. In this article, we will summarize the bulls’ thesis on ABT.

You may not immediately recognize the name Abbott Laboratories (NYSE: ABT), but you've probably come into close contact with one of the company's many products -- from a coronavirus test to Ensure ...

Abbott Laboratories' business, if not exciting, is resilient and consistent. The company is a leader in multiple markets and has attractive growth avenues. The medical device leader boasts a strong ...

Abbott Laboratories (NYSE:ABT) is preparing to release its quarterly earnings on Thursday, 2026-01-22. Here's a brief overview of what investors should keep in mind before the announcement. Analysts ...